PierianDx announced a strategic partnership with RTI International to help solve the problem of translating complex genomic data into actionable clinical insight to advance precision medicine. The partnership includes investment and collaboration on product, service and market expansion.
“Next-generation sequencing and genomic medicine is a rapidly evolving scientific field with potential to advance clinical risk detection, disease identification, prevention, and personalized treatment,” said Wayne Holden, PhD, president and CEO of RTI International. “PierianDx’s mission of advancing precision medicine by turning DNA and RNA into actionable clinical insight with leading academic medical centers, cancer centers, health systems, and commercial laboratories is well aligned with RTI’s mission of improving the human condition by turning knowledge into practice.”
Through a combination of a highly curated uniquitous knowledgebase, cloud-based software, and clinical lab enablement services, PierianDx simplifies the process of translating complex genomic data into patient-specific diagnosis and treatments. PierianDx’s software platform, the Clinical Genomics WorkSpace (CGW), streamlines accurate analysis, interpretation, and reporting for clinical labs seeking to expand NGS testing and personalized medicine.
Since its formation in 2014, PierianDx has extended the capability of its knowledgebase and clinical workflow, building one of the most comprehensive clinical genomics platforms in the industry. The PierianDx Partner Sharing Network includes more than 50 members that utilize shared genomic data to target patient-specific diagnosis and treatments for cancers and hereditary diseases.
“Our partnership and investment in PierianDx fits well with our strategic investment program,” said Matt Jenkins, vice president and head of corporate development at RTI. “We are excited to be partnering with the management team and existing investors and hope to contribute RTI’s expertise and relationships to accelerate PierianDx’s impact. We will collaborate with clinical research and oversight entities and pharmaceutical research organizations to drive further acceptance and adoption of NGS testing.”